Posted from: Monday, August 01, 2016 - 01:58 PM - Present

Dexilant Indication Expanded

July 11, 2016 – The U.S. FDA approved an expanded indication for Dexilant® (dexlansoprazole), a proton pump inhibitor (PPI) for treating stomach acid-related disorders. Dexilant, manufactured by Takeda was previously indicated for use in individuals at least 17 years of age. Dexilant is now indicated for treating gastroesophageal reflux disease (GERD) and healing of erosive esophagitis (EE) in patients 12 years of age and older. 

 

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Monday, April 24, 2017 - 06:05 PM.